Cefiderocol (ANGER) Trial Outcomes

Julie summarizes the ANGER trial: cefiderocol met noninferiority overall but signaled higher mortality in carbapenem‑resistant and MBL subgroups.

Play episode from 01:14:11

Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!